Overview
Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Completed
Trial end date:
2006-10-01
2006-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2 diabetes ) or placebo. The drug is a "DPP4 inhibitor"Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Phenomix
Criteria
Inclusion Criteria:- Type 2 diabetes mellitus treatment with metformin +/- TZD
Exclusion Criteria:
- Type 1 diabetes mellitus